• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

饮食对免疫检查点抑制剂(ICIs)抗肿瘤治疗反应的影响。

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors.

作者信息

Zhang Xin, Li Huiqin, Lv Xiupeng, Hu Li, Li Wen, Zi Meiting, He Yonghan

机构信息

Department of Clinical Nutrition, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.

State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650201, China.

出版信息

Life (Basel). 2022 Mar 11;12(3):409. doi: 10.3390/life12030409.

DOI:10.3390/life12030409
PMID:35330159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8951256/
Abstract

Immunotherapy has revolutionized the established therapeutics against tumors. As the major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable success in the treatment of malignancies. However, the clinical gains are far from universal and durable, because of the primary and secondary resistance of tumors to the therapy, or side effects induced by ICIs. There is an urgent need to find safe combinatorial strategies that enhance the response of ICIs for tumor treatment. Diets have an excellent safety profile and have been shown to play pleiotropic roles in tumor prevention, growth, invasion, and metastasis. Accumulating evidence suggests that dietary regimens bolster not only the tolerability but also the efficacy of tumor immunotherapy. In this review, we discussed the mechanisms by which tumor cells evade immune surveillance, focusing on describing the intrinsic and extrinsic mechanisms of resistance to ICIs. We also summarized the impacts of different diets and/or nutrients on the response to ICIs therapy. Combinatory treatments of ICIs therapy with optimized diet regimens own great potential to enhance the efficacy and durable response of ICIs against tumors, which should be routinely considered in clinical settings.

摘要

免疫疗法彻底改变了针对肿瘤的既定治疗方法。作为主要的免疫疗法,免疫检查点抑制剂(ICI)在恶性肿瘤治疗中取得了显著成功。然而,由于肿瘤对该疗法的原发性和继发性耐药性,或ICI诱导的副作用,临床获益远非普遍且持久。迫切需要找到安全的联合策略来增强ICI对肿瘤治疗的反应。饮食具有极佳的安全性,并且已被证明在肿瘤预防、生长、侵袭和转移中发挥多方面作用。越来越多的证据表明,饮食方案不仅能增强肿瘤免疫疗法的耐受性,还能提高其疗效。在这篇综述中,我们讨论了肿瘤细胞逃避免疫监视的机制,重点描述了对ICI耐药的内在和外在机制。我们还总结了不同饮食和/或营养物质对ICI治疗反应的影响。ICI治疗与优化饮食方案的联合治疗具有极大潜力,可增强ICI对肿瘤的疗效和持久反应,这在临床环境中应常规予以考虑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f83/8951256/e1e3f20d4b79/life-12-00409-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f83/8951256/e1e3f20d4b79/life-12-00409-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f83/8951256/e1e3f20d4b79/life-12-00409-g001.jpg

相似文献

1
Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors.饮食对免疫检查点抑制剂(ICIs)抗肿瘤治疗反应的影响。
Life (Basel). 2022 Mar 11;12(3):409. doi: 10.3390/life12030409.
2
Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.淋巴瘤中免疫检查点抑制的耐药机制:聚焦肿瘤微环境
Front Pharmacol. 2023 Mar 7;14:1079924. doi: 10.3389/fphar.2023.1079924. eCollection 2023.
3
Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies.免疫检查点抑制剂在胃肠道恶性肿瘤中的作用
J Clin Med. 2020 Aug 6;9(8):2533. doi: 10.3390/jcm9082533.
4
Understanding and overcoming resistance to immunotherapy in genitourinary cancers.了解并克服泌尿生殖系统癌症的免疫治疗抵抗。
Cancer Biol Ther. 2024 Dec 31;25(1):2342599. doi: 10.1080/15384047.2024.2342599. Epub 2024 Apr 17.
5
[Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy].[肿瘤治疗中与免疫检查点抑制剂相关的预测生物标志物的进展]
Sheng Wu Gong Cheng Xue Bao. 2023 Apr 25;39(4):1403-1424. doi: 10.13345/j.cjb.220650.
6
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.阻断转化生长因子-β信号通路以增强免疫检查点抑制剂的疗效
Onco Targets Ther. 2019 Nov 11;12:9527-9538. doi: 10.2147/OTT.S224013. eCollection 2019.
7
Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer.非小细胞肺癌免疫检查点抑制剂的临床试验研究现状与应用
Front Oncol. 2023 Sep 1;13:1213297. doi: 10.3389/fonc.2023.1213297. eCollection 2023.
8
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.免疫检查点抑制剂联合疗法;新前沿。
Cancer Cell Int. 2022 Jan 3;22(1):2. doi: 10.1186/s12935-021-02407-8.
9
Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.腔道胃肠道恶性肿瘤中的免疫检查点抑制剂:超越微卫星高度不稳定/错配修复缺陷、肿瘤突变负荷和程序性死亡配体1
Immunotherapy. 2022 Aug;14(11):885-902. doi: 10.2217/imt-2022-0012. Epub 2022 Jun 13.
10
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.免疫检查点抑制剂在癌症治疗中的应用:临床影响及反应和耐药的机制。
Annu Rev Pathol. 2021 Jan 24;16:223-249. doi: 10.1146/annurev-pathol-042020-042741. Epub 2020 Nov 16.

引用本文的文献

1
Tumor microenvironment and immune-related myositis: addressing muscle wasting in cancer immunotherapy.肿瘤微环境与免疫相关肌炎:解决癌症免疫治疗中的肌肉萎缩问题
Front Immunol. 2025 May 2;16:1580108. doi: 10.3389/fimmu.2025.1580108. eCollection 2025.
2
Age- and diet-instructed metabolic rewiring of the tumor-immune microenvironment.年龄和饮食指导下的肿瘤免疫微环境代谢重塑。
J Exp Med. 2025 Jun 2;222(6). doi: 10.1084/jem.20241102. Epub 2025 Apr 11.
3
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential.

本文引用的文献

1
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges.PD1/PD-L1抑制剂在肿瘤学中的多种用途:机遇与挑战。
Front Oncol. 2021 Nov 17;11:771335. doi: 10.3389/fonc.2021.771335. eCollection 2021.
2
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.美国晚期黑色素瘤患者免疫疗法日间输注时间对总生存期的影响(MEMOIR):一项单中心纵向研究的倾向评分匹配分析。
Lancet Oncol. 2021 Dec;22(12):1777-1786. doi: 10.1016/S1470-2045(21)00546-5. Epub 2021 Nov 12.
3
饮食干预对人类疾病的影响:分子机制与治疗潜力。
Signal Transduct Target Ther. 2024 Mar 11;9(1):59. doi: 10.1038/s41392-024-01771-x.
4
Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond.解开饮食谜题:探索饮食、营养保健品和补充剂对膀胱癌风险、预后及免疫治疗疗效的影响:来自BLOSSOM研究及其他研究的见解
Oncol Ther. 2024 Jun;12(2):189-195. doi: 10.1007/s40487-024-00266-7. Epub 2024 Feb 28.
5
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer.免疫相关不良反应的出现与接受帕博利珠单抗治疗早期三阴性乳腺癌患者的病理完全缓解相关。
Oncoimmunology. 2023 Nov 13;12(1):2275846. doi: 10.1080/2162402X.2023.2275846. eCollection 2023.
6
What We Have Learned About Combining a Ketogenic Diet and Chemoimmunotherapy: a Case Report and Review of Literature.我们从生酮饮食与化学免疫疗法联合应用中所学到的:一例病例报告及文献综述
Fed Pract. 2023 Aug;40(Suppl 3):S98-S104. doi: 10.12788/fp.0399. Epub 2023 Aug 14.
7
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.肠道微生物组:从生物标志物到肺癌患者免疫治疗反应的新型治疗策略。
Curr Oncol. 2023 Oct 24;30(11):9406-9427. doi: 10.3390/curroncol30110681.
8
Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors.饮食中 HDAC2i 在接受 PD-1/PD-L1 抑制剂治疗的乳腺癌患者中的潜力。
Nutrients. 2023 Sep 14;15(18):3984. doi: 10.3390/nu15183984.
9
Analysis of the Gut Microbiome and Dietary Habits in Metastatic Melanoma Patients with a Complete and Sustained Response to Immunotherapy.对免疫疗法有完全且持续反应的转移性黑色素瘤患者的肠道微生物群和饮食习惯分析
Cancers (Basel). 2023 Jun 4;15(11):3052. doi: 10.3390/cancers15113052.
10
Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.免疫疗法:在结直肠癌中的新辅助、辅助和一线治疗中的最新进展及其未来。
Cells. 2023 Jan 8;12(2):258. doi: 10.3390/cells12020258.
Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers.
晚期尿路上皮癌治疗的生物治疗进展
Biologics. 2021 Nov 1;15:441-450. doi: 10.2147/BTT.S290311. eCollection 2021.
4
Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis.免疫检查点抑制剂在结直肠癌中的疗效和安全性:系统评价和荟萃分析。
Int J Colorectal Dis. 2022 Jan;37(1):251-258. doi: 10.1007/s00384-021-04028-z. Epub 2021 Oct 29.
5
Nutrition and Cancer Risk from the Viewpoint of the Intestinal Microbiome.从肠道微生物组的角度看营养与癌症风险。
Nutrients. 2021 Sep 23;13(10):3326. doi: 10.3390/nu13103326.
6
Relative Efficacy of Vitamin D and Vitamin D in Improving Vitamin D Status: Systematic Review and Meta-Analysis.维生素 D 和维生素 D 制剂在改善维生素 D 状态方面的相对疗效:系统评价和荟萃分析。
Nutrients. 2021 Sep 23;13(10):3328. doi: 10.3390/nu13103328.
7
Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma.表皮生长因子受体(EGFR)突变型肺腺癌对奥希替尼耐药时HLA I类分子呈递的免疫肽组及I类相互作用组的改变
Cancers (Basel). 2021 Oct 4;13(19):4977. doi: 10.3390/cancers13194977.
8
Embracing cancer immunotherapy with vital micronutrients.用关键微量营养素接受癌症免疫疗法。
World J Clin Oncol. 2021 Sep 24;12(9):712-724. doi: 10.5306/wjco.v12.i9.712.
9
Vitamin B6 in Health and Disease.维生素 B6 在健康与疾病中的作用
Nutrients. 2021 Sep 17;13(9):3229. doi: 10.3390/nu13093229.
10
Trace elements under the spotlight: A powerful nutritional tool in cancer.微量元素备受关注:癌症防治的有力营养工具
J Trace Elem Med Biol. 2021 Dec;68:126858. doi: 10.1016/j.jtemb.2021.126858. Epub 2021 Sep 14.